Adult-onset Still disease
ORPHA:829DiseaseNot applicableAdult, Elderly
Фенотипы (HPO)59
Очень частый (80–99%)14
HP:0000988Skin rash
HP:0000989Pruritus
HP:0001369Arthritis
HP:0001386Joint swelling
HP:0001945Fever
HP:0001974Leukocytosis
HP:0002829Arthralgia
HP:0003281Increased circulating ferritin concentration
HP:0003565Elevated erythrocyte sedimentation rate
HP:0005059Arthralgia/arthritis
HP:0010783Erythema
HP:0011227Elevated circulating C-reactive protein concentration
HP:0011897Neutrophilia
HP:0012378Fatigue
Частый (30–79%)18
HP:0001744Splenomegaly
HP:0001824Weight loss
HP:0001903Anemia
HP:0002027Abdominal pain
HP:0002102Pleuritis
HP:0002202Pleural effusion
HP:0002240Hepatomegaly
HP:0002716Lymphadenopathy
HP:0002910Elevated circulating hepatic transaminase concentration
HP:0003155Elevated circulating alkaline phosphatase concentration
HP:0003326Myalgia
HP:0005828Transient pulmonary infiltrates
HP:0008940Generalized lymphadenopathy
HP:0025406Asthenia
HP:0025439Pharyngitis
HP:0033050Pharyngalgia
HP:0040186Maculopapular exanthema
HP:6000933Koebner Phenomenon
Периодический (5–29%)18
HP:0000093Proteinuria
HP:0001298Encephalopathy
HP:0001701Pericarditis
HP:0001733Pancreatitis
HP:0002018Nausea
HP:0002039Anorexia
HP:0002098Respiratory distress
HP:0002840Lymphadenitis
HP:0002923Rheumatoid factor positive
HP:0003119Abnormal circulating lipid concentration
HP:0003493Antinuclear antibody positivity
HP:0005528Bone marrow hypocellularity
HP:0006515Interstitial pneumonitis
HP:0012115Hepatitis
HP:0012156Hemophagocytosis
HP:0012544Elevated circulating aldolase concentration
HP:0012819Myocarditis
HP:0100773Cartilage destruction
Очень редкий (1–4%)6
HP:0000509Conjunctivitis
HP:0000554Uveitis
HP:0005521Disseminated intravascular coagulation
HP:0011034Amyloidosis
HP:0033430Non-infectious meningitis
HP:0100534Episcleritis
Исключён (0%)3
HP:0002665Lymphoma
HP:0031693Severe Epstein Barr virus infection
HP:0100806Sepsis
Эпидемиология8
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.16 | France | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.13 | Japan | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.9 | Japan | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.4 | Norway | Value and class |
| Point prevalence | 1-9 / 100 000 | 6.9 | Norway | Value and class |
| Point prevalence | 1-9 / 100 000 | — | Europe | Class only |
| Annual incidence | 1-9 / 1 000 000 | 0.62 | Turkey | Value and class |
| Point prevalence | 1-9 / 100 000 | 6.77 | Turkey | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)